Privia Health Group, Inc. vs GeneDx Holdings Corp., two Medical Services stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Privia runs debt-free at a 1.6 current ratio, GeneDx at 0.39 turns with a 3.1 ratio of runway, and both balance sheets exist to buy time for opposite experiments: Privia's physician-enablement platform already earns, barely, a 0.97% net margin, while GeneDx's genomic-testing buildout burns a negative 56.2% operating margin against a 66.7% gross. Neither has an earnings multiple. Free cash favors Privia, 4.1% against negative 1.4%. The market values the near-break-even platform at $3B and the far-from-it sequencer at $2B, a surprisingly small gap given the distance between their income statements; genomics dreams, evidently, discount at a friendlier rate than primary-care logistics.
Comparison updated 2026-07-10.
| Metric | PRVA | WGS |
|---|---|---|
| Price | $25.55 | $69.86 |
| Market cap | $3.3B | $2.0B |
| Sector | Medical Services | Medical Services |
| Stage | Growth | Growth |
| P/B | 4.15 | 8.06 |
| P/S | 1.49 | 4.63 |
| EV/EBITDA | 61.3 | — |
| Revenue growth | +24.8% | +35.3% |
| Gross margin | — | 66.7% |
| Operating margin | 1.2% | -56.2% |
| Net margin | 1.0% | -17.6% |
| Return on equity | 2.7% | -30.6% |
| Return on assets | 1.5% | -15.4% |
| Return on invested capital | 3.6% | -14.7% |
| FCF yield | 4.1% | -1.4% |
| Debt / equity | 0.00 | 0.39 |
| Current ratio | 1.61 | 3.09 |
| Altman Z (solvency) | 5.04 | 1.84 |
| Piotroski F (quality) | 5 / 9 | 1 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.